Evaluation of WO2012080456 and WO2012080457; Boheringer Ingleheim's first CXCR2 antagonists

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.23, Iss.3, 2013-03, pp. : 383-388

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Boehringer Ingleheim's selective glucocorticoid receptor agonist development candidate: evaluation of WO2010141331, WO2010141332 and WO2010141333

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 7, 2011-07 ,pp. : 1137-1142

Informa Healthcare

Access to resources Recommend Favorite

Antagonists of IL-1R: a patent evaluation (WO2012122985)

By Sette Claudio

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 7, 2013-07 ,pp. : 911-914

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2012078210 – development process for the preparation of a DP2 receptor antagonist; Ironwood's first development DP2 antagonist

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 10, 2012-10 ,pp. : 1257-1261

Informa Healthcare

Access to resources Recommend Favorite

Heterocyclic compounds and their uses: a patent evaluation of WO2010151735A2

By Scozzafava Andrea Supuran Claudiu T

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 5, 2011-05 ,pp. : 803-806

Informa Healthcare

Access to resources Recommend Favorite

Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756)

By Deng Xianming S. Gray Nathanael

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 6, 2012-06 ,pp. : 709-713

Informa Healthcare

Access to resources Recommend Favorite